Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Published by:
Ivey Publishing (2021)
Version:
2021-02-12
Revision date:
19-Mar-2021
Length:
11 pages
Data source:
Published sources

Abstract

In July 2020, Eastman Kodak Company (Kodak) received a USD765 million loan from the US federal government for drug component manufacturing. Kodak's chief executive officer (CEO) was confident about the company's ability to excel in the pharmaceutical industry. However, critics cited several concerns, such as workforce availability and Kodak's lack of experience in the pharma business. The CEO believed that Kodak's expertise in advanced chemicals and manufacturing could drive the firm's success in the pharma business. Would Kodak be able to establish its mark in the US pharma industry? What challenges was Kodak likely to face?

Teaching and learning

This item is suitable for undergraduate and postgraduate courses.

Topics

Core competency; Diversification; Insider trading; Pharmaceutical industry; Stock options; Low-cost strategy; Dynamic capabilities; Corporate reputation; General management/strategy
Location:
Industry:
Size:
Large
Other setting(s):
2020

Access this item

casecent.re/p/175353
View our pricing guide
or to see prices.